Recent Headlines
Carrington Laboratories and Racing Legend Johnny Rutherford Sign Endorsement and Personal Agreement
Carrington Laboratories, Inc. (Nasdaq: CARN) announced it has entered into a one-year endorsement and personal services agreement with racing legend Johnny Rutherford. The partnership provides a platform for Carrington to reach the rapidly growing and attractive racing enthusiast consumer... - February 17, 2007 - Carrington Laboratories
Twenty-Four Colorado Companies Exhibited at the West Coast's Largest Design and Manufacturing Show, MD&M West
Twenty-four Colorado-based companies exhibited at the 23rd annual Medical Device & Manufacturing (MD&M) West show in Anaheim, CA, February 13-15. Colorado has a strong medical device manufacturing sector and was well represented at the MD&M trade show and conference. Several of Colorado’s regional economic development agencies were also in Anaheim assisting exhibiting companies and promoting the State of Colorado as a great place for doing business. - February 16, 2007 - Colorado BioScience Association
HiTIS - Life Science & Biotech Intelligence, A Global Life Sciences Industry Focused Competitive Intelligence Firm, Launched Skin Diseases Drug Development Weekly
HiTIS - life science & biotech intelligence, a global life sciences industry focused competitive intelligence firm, launched Skin Diseases Drug Development Weekly while the American Academy of Dermatology held its 65th annual meeting. - February 12, 2007 - HiTIS - Life Science & Biotech Intelligence
Dosing Convenience is Mandatory to Keep Pace in the Pipeline Race of GLP-1 Analogs for Type 2 Diabetes
The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide... - February 06, 2007 - La Merie Business Intelligence
Overview on 2006 Sales of Top 20 Biologics to Be Released on February 26
A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. - February 05, 2007 - La Merie Business Intelligence
NeuroscienceCME.com Launches New Sleep and Wake Medicine Clinical Knowledge Center
Web-based resource for sleep professionals offers education, guidelines, references, etc. - January 24, 2007 - CME Outfitters, LLC
Diluted Insulin Injections for Type 1 Diabetes Sufferers Are Now Available at Teregen Labs
Pharmacists at Teregen Labs can prepare diluted insulin in response to the growing need not met through retail pharmacies. When a Diluted Insulin Injection is needed, often when a patient is on an insulin pump, things typically get worse for diabetes sufferers. Teregen Labs regularly dilutes Insulin for diabetes sufferers with a valid prescription from their physician faxed into their pharmacy for an affordable price. - January 16, 2007 - Teregen Labs
The Right Balance Drives the Field of PPAR Agonist R&D
A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. - January 12, 2007 - La Merie Business Intelligence
Cincinnati Children's Named One of Top Five Children's Hospitals in Child Magazine's Top Children's Hospitals Survey
Cincinnati Children's Hospital Medical Center is among the five best children's hospitals in the United States overall, and among the top five in the nation for pediatric cancer care and neonatal care, according to Child magazine's prestigious Ten Best Children's Hospital survey. Child magazine... - January 05, 2007 - Cincinnati Children's Hospital Medical Center
Weekly Monitor Drug and Diagnostic Development in Neurodegenerative Diseases
HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, recently launched Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence Weekly - November 30, 2006 - HiTIS - Life Science & Biotech Intelligence
HiTIS - Life Science & Biotech Intelligence Expands Web Presence with www.txpreview.com
HiTIS - life science & biotech intelligence, a European life sciences industry- focused competitive intelligence firm, has released its corporate website. - November 23, 2006 - HiTIS - Life Science & Biotech Intelligence
Put an Eye on the Weekly Electronic Publication Covering Drug and Device-Based Available Treatments, Current Research and Upcoming Therapies Addressing Eye Disorders
HiTIS - life science & biotech intelligence, a life sciences industry focused competitive intelligence firm, has released the 26th weekly issue of its Eye Care industry competitive intelligence publication: Eye Therapies Competitive Intelligence Weekly (ETCI Weekly). - November 20, 2006 - HiTIS - Life Science & Biotech Intelligence
Reputed Orthopaedic Surgeon to Join Business Intelligence Services Firm HiTIS Team as Scientific and Medical Advisor
Life science industry-focused competitive intelligence services practice adds outstanding orthopaedics expertise to founding team to develop new competitive intelligence periodical reports. - October 17, 2006 - HiTIS - Life Science & Biotech Intelligence
Delivery Improvements of the AMD-drug Lucentis on the Way
The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection. - September 20, 2006 - La Merie Business Intelligence
InViragen Announces Exclusive Patent License Agreement with the Centers for Disease Control
InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging infectious diseases worldwide, has entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention (CDC). The licensed technology is applicable to vaccines against multiple viral diseases, including dengue fever and West Nile disease. Dengue fever threatens 2.5 billion people worldwide as well as travelers to tropical countries. - September 14, 2006 - Colorado BioScience Association
Biologics Define New Standard of Therapy in Psoriasis
Anti-TNF agents set the new gold standard of psoriasis treatment which could be outperformed by smarter next generation biologics and small molecules in safety and convenience. - September 08, 2006 - La Merie Business Intelligence
Leading Colorado Biotechnology and Medical Device Companies Selected to Present at BIO Mid-America VentureForum
Five Colorado-based companies have been selected to present at the Biotechnology Industry Organization (BIO) Mid-America VentureForum to be held September 25-27th at the InterContinental Hotel in Cleveland, Ohio. These companies are among more then 50 companies selected by venture capitalists from the nation’s leading firms who serve on BIO’s advisory board. - September 07, 2006 - Colorado BioScience Association
ApopLogic Pharmaceuticals Wins the Second Annual Faegre & Benson Venture Showcase Award, Presented at BioWest 2006
ApopLogic Pharmaceuticals has won the second annual Faegre & Benson Venture Showcase Award at the BioWest 2006 conference in Denver. The announcement is made by Chris Shapard, bioscience director at the Colorado Office of Economic Development and International Trade (OEDIT), who says the $10,000 Venture Showcase Award was again provided by the Faegre & Benson law firm and announced at the Colorado Bioscience Association (CBSA) Awards banquet held Thurs. evening at the Colo. Convention Center. - August 25, 2006 - Colorado BioScience Association
Cincinnati Children's Celebrates Patients and Families with Inaugural Five-Mile Pledge Walk
Thousands of patients, families and supporters of Cincinnati Children's Hospital Medical Center will gather at Coney Island from 10 am - 2 pm Saturday, November 4, for the inaugural Cincinnati Walks for Kids. This new fundraising initiative, designed to celebrate and honor the patients and... - August 25, 2006 - Cincinnati Children's Hospital Medical Center
Colorado BioScience Association Announces Winners of Its 2006 Awards Program, Honoring the Best of Colorado's Bioscience Industry
The Colorado BioScience Association (CBSA) has released winners of its 2006 Awards Program. Official presentation of the awards occurs Thursday evening, August 24, 6:30 – 8:30 p.m., at the CBSA’s annual awards banquet. Held in conjunction with the 2006 BioWest conference at the Colorado Convention Center, registration information is available at the 2006 BioWest Conference website. - August 18, 2006 - Colorado BioScience Association
The Crowded Field of VEGF and VEGF-R Targeting Drugs
The versatility of the vascular endothelial growth factor (VEGF) signalling pathway as a validated target and its excellent tractability explain a crowded field of drugs of all classes. - August 17, 2006 - La Merie Business Intelligence
A Full Pipeline of Follow-on TNF-Antagonists
The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds including improved TNF-antagonists and molecules originating from new technologies. - August 02, 2006 - La Merie Business Intelligence
Five Top Colorado Bioscience Company CEOs Present at This Year’s BioWest Investor Forum
CEOs from five of Colorado’s top bioscience companies will present at the BioWest 2006 Investor Forum on August 24th – registration is still open for the two-day BioWest event, which is the Rocky Mountain Region’s premier bioscience conference and expo. CEOs featured in the Investor Forum include Paul Berns, Allos Therapeutics; John Serino, Encision; Bill Freytag, Myogen; Patrick Mahaffy, Pharmion; and Ken Collins, Replidyne. - July 28, 2006 - Colorado BioScience Association
Seven Finalists Selected for The BioWest 2006 Venture Showcase Competition, Presenting World-Changing Technologies
Novel cancer drugs; innovative treatments for blood cancers and clotting; new ways to attack inflammatory and infectious diseases; ground-breaking compounds to treat osteoporosis and metastatic bone disease; pioneering devices for orthopedic surgery; commercializing biofuels from algae; and revolutionary wearable rehabilitation systems comprise the seven finalists in this year’s BioWest Veture Showcase competition. - July 11, 2006 - Colorado BioScience Association
Biogenerics and New Technologies Compete with 1st Generation Major Products
The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions. - June 20, 2006 - La Merie Business Intelligence
Baxter Black and Ira Flatow Lead the Lineup of Presenters for Biowest 2006, Now Open for Registration
Registration is now open for the Rocky Mountain Region’s Premier Bioscience Conference and Expo, BioWest 2006. More than 750 participants are expected at this year’s event, August 23-24, at the Colorado Convention Center in Denver. America’s “Cowboy Poet” Baxter Black and NPR Science Friday® host Ira Flatow are the headliners for Biowest 2006, along with the presentation, “Where Innovation Happens” from Federal Reserve Executive Michael Orlando. - June 06, 2006 - Colorado BioScience Association
Imminent Launches of New EPO Products and Consolidation of the Biogenerics Field
The Business Intelligence firm La Merie S.L. reported today changes in the field of erythropoiesis stimulating agents (ESA) observed in a follow-up analysis. The first launch of a new ESA in Europe is expected to be Shire’s epoetin omega in the first half of 2007 to be followed by... - June 03, 2006 - La Merie Business Intelligence
Localized Delivery of PDE-4 Inhibitors to Open the Therapeutic Window
The Localized delivery of phosphodiesterase-4 (PDE-4) inhibitors appears to be short term solution to overcome the dose-limiting side effects of severe nausea and emesis occurring after oral administration. In the long-term, subtype-selective PDE-4 inhibitors and combination regimens may help to improve the therapeutic index. - May 31, 2006 - La Merie Business Intelligence
WellAware™ Error-Free Light Guided Manual Pipetting System is Now Application Based
BioTX has finished the development of an application based, light guided manual pipetting system called WellAware which is ideal for forensic, paternity, life science, pharmaceutical, preclinical and chemistry labs. WellAware provides lab managers with an inexpensive alternative or supplement to full automation. WellAware is configured right out of the box for PCR, DNA sequencing, genotyping, microplate transpositions, dilutions, normalizations, microplate reformatting and cherry-picking. - May 25, 2006 - BioTX Automation, Inc.
The Next Generation of Interferons Needs Improvement in Efficacy and Safety
The interferon alpha market is smaller than the interferon beta market, but is characterized by far more products and R&D projects. Conversion of the interferon alpha market to pegylated products explains why new R&D is focused on interferon alpha variants or other subtypes with improved pharmacodynamic and safety properties. - May 19, 2006 - La Merie Business Intelligence
First DNA Testing Lab to Promise Fast Results with a Money-back Guarantee
New paternity test guarantee may benefit more than 1 million people each year. - May 18, 2006 - Identigene
RNA Interference (RNAi) is Coming of Age as a Therapeutic Modality
The Business Intelligence firm La Merie S.L. reported today that the RNAi therapeutic pipeline is rapidly filling and advancing towards clinical development. Four RNAi therapeutic projects are in early clinical development. At least 32 RNAi projects are in preclinical development in a variety of... - May 10, 2006 - La Merie Business Intelligence
BioWest 2006 Organizers Seek the Best and Brightest of the Rocky Mountain Region’s Bioscience Start-Ups for the Venture Showcase Competition
BioWest, The Rocky Mountain Region’s Premier Bioscience Conference and Expo, is again looking for the best bioscience start-ups in the region as candidates for the $10,000 Faegre & Benson Venture Showcase Award. Seven companies will be chosen to present at the Showcase in August, which will be judged by a panel of national venture capitalists. Deadline for entry is June 8, 2006. - May 09, 2006 - Colorado BioScience Association
2006-2007 Colorado Bioscience Magazine Unveiled At Colorado BioScience Association 2006 Annual Membership Meeting
Colorado BioScience Association released new 76-page issue of Bioscience Colorado Magazine at the 2006 Annual Membership Meeting. In addition, seven new appointments were made to the Board of Directors, along with eight reappointments; 2006 Corporate Sponsors were introduced; and Brandon Shaffer, Colorado State Senator District 17, was presented the national Biotechnology Industry Organization Legislator of the Year Award. - April 18, 2006 - Colorado BioScience Association
Seven New Board Members Named To The Colorado BioScience Association Board Of Directors At The 2006 Annual Membership Meeting
Seven new appointments were made to the Board of Directors of Colorado BioScience Association at its 2006 Annual Membership Meeting, along with eight reappointments. In addition, the 2006 Corporate Sponsors were released; Brandon Shaffer, Colorado State Senator District 17, was presented the national Biotechnology Industry Organization Legislator of the Year Award; and the 2006-2007 Bioscience Colorado Magazine was unveiled to members at the event. - April 18, 2006 - Colorado BioScience Association
State Senator Brandon Shaffer Receives National BIO Legislator of the Year Award at Colorado BioScience Association 2006 Annual Membership Meeting
Brandon Shaffer, Colorado State Senator District 17, was presented the national Biotechnology Industry Organization Legislator of the Year Award at the Colorado BioScience Association 2006 Annual Membership Meeting. The award was presented by Amgen Colorado’s Eric Bergenson. Senator Shaffer was singled out nationally for his ongoing and extensive support of the bioscience industry in the state. - April 18, 2006 - Colorado BioScience Association
Antibodies are the First Wave of IGF-1R Antagonists for Cancer Therapy
At least six fully human or humanized antibodies against insulin-like growth factor-1 receptor (IGF-1R) are in early clinical development or close to phase I. - March 07, 2006 - La Merie Business Intelligence
Dawn has Broken for Obesity Treatment with Cannabinoid Receptor (CB1) Antagonists
Tremendous impetus to discovery of novel CB1 antagonists by first-in-class CB1 receptor antagonist rimonabant under review by FDA and EMEA - February 22, 2006 - La Merie Business Intelligence
Top 20 Biologics Now with Sales of US$ 37.7 Bln in 2005
The Top 20 blockbuster recombinant proteins and antibodies achieved record sales of US$ 37.7 bln in the year 2005 while combined sales of the 12 Top selling classes of recombinant proteins and antibodies reached the US$ 50 bln threshold. - February 15, 2006 - La Merie Business Intelligence
Dosing Convenience Mandates the Pipeline of Glucagon-like Peptide-1 (GLP-1) Analogs for Type 2 Diabetes
Twice-daily injection is the benchmark set by exenatide, the first GLP-1 analog launched in the US by Lilly in June 2005 and half-year sales of US$ 74.6 mln, which now faces competition by GLP-1 analog treatment modalities with less frequent dosing. - February 07, 2006 - La Merie Business Intelligence
Emerging Diabetes Drugs in Early Development
The complexity of glucose metabolism and the number of cellular processes affected by diabetes provides ample space for new drug targets and for first-in-class molecules. Some of them have reached or are close to early clinical development in type 2 diabetes. - January 31, 2006 - La Merie Business Intelligence
High Interest in Inhibitors of the Novel Target Sodium-dependent Glucose (co-) Transporter (SGLT) for Therapy of Type 2 Diabetes
A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 diabetes. SGLT inhibitors do not intervene with glucose metabolism, thus being complementary to mainstream approaches to glucose regulation, i.e. PPAR agonists, DPP-IV antagonists and GLP-1 analogues. - January 24, 2006 - La Merie Business Intelligence
Pharm-Olam International Announces $13.4 Million Contracts to Provide Services for Clinical Trials
Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announced the signing of three contracts with an aggregate value of $13.4 million. The contracts involve patient recruitment, site selection, project management, biostatistics, monitoring, and regulatory affairs in the therapeutic areas of pain, cardiovascular disease, and ophthalmology. - January 11, 2006 - Pharm-Olam International
Herbion and Uzbek Health Sector Delegation – An interesting Get Together
Continuing its hospitable tradition, Herbion Pakistan Pvt. Ltd. organized a memorable event extending a warm welcome to the members of Uzbekistan Health Sector Delegation on the pleasant evening of December 13, 2005 by having Corporate get together followed by an interesting boat ride and dinner. - December 17, 2005 - Herbion International
Hamdard University Students Study Tour Herbion
A group of 16 students and 3 faculty members from Hamdard University, Karachi, Pakistan visited Herbion Pakistan (Private) Limited, the manufacturing unit of the Herbion Group of Companies located at Korangi, Karachi on December 8, 2005. - December 16, 2005 - Herbion International
Christine Shapard To Leave Governor’s Office In January To Join Colorado BioScience Association
Christine Shapard, Director of Biosciences and Emerging Technologies for the Governor’s Office of Economic Development and International Trade (OEDIT) for the past two years, will join the Colorado BioScience Association (CBSA) in January as the association’s Director of Marketing and Communications. During 2006, Shapard will maintain a 25% appointment with OEDIT tracking and completing major efforts currently in progress. - December 09, 2005 - Colorado BioScience Association
Pharm-Olam International Releases Results of 2005 Client Satisfaction Survey
Revealing continuing improvement in levels of customer satisfaction and loyalty, Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology, and medical device industries, has released the most recent results of its formal survey. - December 09, 2005 - Pharm-Olam International
Cardiovascular safety determines the direction of PPAR agonist R&D
The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %). - November 28, 2005 - La Merie Business Intelligence
Pharm-Olam International Completes Enrollment of 700 Patient Global Pivotal Phase III Clinical Trial for Metastatic Breast Cancer
HOUSTON, TEXAS – November 27, 2005 – Pharm-Olam International Ltd. (POI) has completed enrollment of a 700 patient pivotal trial for the treatment of metastatic and recurrent breast cancer. Enrollment of the Phase III clinical trial was achieved on schedule in just 18 months and... - November 25, 2005 - Pharm-Olam International
Competition is Needed in the Follicle Stimulating Hormone (FSH) Market
Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta). - November 14, 2005 - La Merie Business Intelligence